State Street
CTNM

State Street’s Contineum Therapeutics CTNM Stock Holding History

State Street’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.98M Buy
425,902
+324,624
+321% +$4.26M ﹤0.01% 2870
2026
Q1 		$1.32M Buy
101,278
+16,850
+20% +$226K ﹤0.01% 3421
2025
Q4 		$965K Buy
84,428
+22,000
+35% +$251K ﹤0.01% 3532
2025
Q3 		$734K Buy
62,428
+33,528
+116% +$270K ﹤0.01% 3579
2025
Q2 		$115K Sell
28,900
-97,964
-77% -$426K ﹤0.01% 3951
2025
Q1 		$886K Buy
126,864
+2,120
+2% +$19.3K ﹤0.01% 3459
2024
Q4 		$1.83M Buy
124,744
+11,178
+10% +$177K ﹤0.01% 3347
2024
Q3 		$2.17M Buy
113,566
+21,760
+24% +$417K ﹤0.01% 3300
2024
Q2 		$1.62M Buy
+91,806
New +$1.48M ﹤0.01% 3385

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street's CTNM Position: Q2 2026 in Review

State Street increased its Contineum Therapeutics (CTNM) stake by 321% in Q2 2026, buying an estimated $4.26M and bringing the position to 425,902 shares worth $6.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2870.

State Street first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • State Street held 425,902 shares of Contineum Therapeutics worth $6.98M as of Q2 2026.
  • State Street bought 324,624 Contineum Therapeutics shares in Q2 2026, an estimated $4.26M.
  • Contineum Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2870 holding.
  • State Street first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.